DE69722621D1 - Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression - Google Patents

Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression

Info

Publication number
DE69722621D1
DE69722621D1 DE69722621T DE69722621T DE69722621D1 DE 69722621 D1 DE69722621 D1 DE 69722621D1 DE 69722621 T DE69722621 T DE 69722621T DE 69722621 T DE69722621 T DE 69722621T DE 69722621 D1 DE69722621 D1 DE 69722621D1
Authority
DE
Germany
Prior art keywords
dna repair
increase sensitivity
inhibitors
inhibiting dna
mediated suppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69722621T
Other languages
German (de)
English (en)
Inventor
A Gjerset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sidney Kimmel Cancer Center
Original Assignee
Sidney Kimmel Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Center filed Critical Sidney Kimmel Cancer Center
Application granted granted Critical
Publication of DE69722621D1 publication Critical patent/DE69722621D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
DE69722621T 1996-07-05 1997-07-02 Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression Expired - Lifetime DE69722621D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/675,887 US6054467A (en) 1996-07-05 1996-07-05 Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
PCT/US1997/012542 WO1998001123A1 (en) 1996-07-05 1997-07-02 Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression

Publications (1)

Publication Number Publication Date
DE69722621D1 true DE69722621D1 (de) 2003-07-10

Family

ID=24712371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722621T Expired - Lifetime DE69722621D1 (de) 1996-07-05 1997-07-02 Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression

Country Status (8)

Country Link
US (2) US6054467A (enExample)
EP (1) EP0910357B1 (enExample)
JP (1) JP2000516207A (enExample)
AT (1) ATE241973T1 (enExample)
AU (1) AU724212B2 (enExample)
CA (1) CA2259960C (enExample)
DE (1) DE69722621D1 (enExample)
WO (1) WO1998001123A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
AU2002230775A1 (en) * 2000-12-13 2002-06-24 Georgetown University Gene therapy for prostate cancer: sensibilization of cells to dn a damaging drugs and radiation
EP1348030B1 (en) * 2001-01-04 2009-11-25 Wadell, Göran Viral vector for gene therapy
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
US20030152549A1 (en) * 2001-12-04 2003-08-14 Palladino Michael A. Methods and apparatus for cell based screening
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
EP1694322A2 (en) * 2003-11-26 2006-08-30 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
KR101527213B1 (ko) * 2004-12-31 2015-06-09 페르 손네 홀름 동물 세포에서 다중 내성을 역전시키기 위한 방법
JP2007119359A (ja) * 2005-10-25 2007-05-17 Fujifilm Corp 癌抑制剤
US20070280905A1 (en) * 2006-06-01 2007-12-06 Shulin Li Prognosis and Systemic Therapy for Treating Malignancy
KR101587687B1 (ko) * 2012-04-27 2016-01-21 가톨릭대학교 산학협력단 Ｓｒ11302 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
WO2017085351A1 (es) * 2015-11-20 2017-05-26 Servicio Andaluz De Salud Derivados del ácido retinoico para el tratamiento de la colestasis
US10722530B2 (en) * 2016-12-23 2020-07-28 Case Western Reserve University Methods of diagnosing and treating cancer
US11911356B2 (en) 2017-12-22 2024-02-27 The Johns Hopkins University Regulation of mutant TERT by BRAF V600E/map kinase pathway through FOS/GABP in human cancer
WO2019207167A1 (en) 2018-04-27 2019-10-31 Fondazione Telethon Therapy of sulfatase deficiencies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
EP0440744B1 (en) * 1988-10-31 1997-12-10 The Regents Of The University Of California Products and methods for controlling the suppression of the neoplastic phenotype
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
ATE199568T1 (de) * 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2712602B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712603B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
AU3670597A (en) 1998-02-02
US20050095226A1 (en) 2005-05-05
EP0910357B1 (en) 2003-06-04
CA2259960C (en) 2008-04-29
EP0910357A1 (en) 1999-04-28
AU724212B2 (en) 2000-09-14
JP2000516207A (ja) 2000-12-05
CA2259960A1 (en) 1998-01-15
ATE241973T1 (de) 2003-06-15
WO1998001123A1 (en) 1998-01-15
US6054467A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
DE69722621D1 (de) Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
EP1490385A4 (en) INHIBITORS OF JAGGED 2 TO INDUCE APOPTOSIS
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE287734T1 (de) Radionukleiide assoziierte nukleotid- polyphosphate zur bilddarstellung von tumoren
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE339208T1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE294811T1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
ATE332970T1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
8332 No legal effect for de